After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Regeneron Pharmaceuticals earns the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

In the preceding three months, 15 analysts have released ratings for Regeneron Pharmaceuticals REGN, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...

Here’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple ...

Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and ...

Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

Shares of Regeneron Pharmaceuticals ( REGN 0.56%), a biotech giant, have been southbound over the past two years as the ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Regeneron Pharmaceuticals (NASDAQ:REGN) in the last three months. The following table provides a ...

Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $8.03 per share in its upcoming release, pointing to a year-over-year decline of 30.5%. It is anticipated that ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock ...